| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Paulson & Co. · John Paulson | $361.2M | 14.0% | 73.26M | — | Q2 2026 |
| Renaissance Technologies | $6.5M | 0.01% | 1.32M | −16% | Q2 2026 |
| Bridgewater Associates · Ray Dalio | $4.3M | 0.02% | 866.28K | +29% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BHC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Leung SandraDirector | Stock Award(Grant) at price 5.83 per share. | 5.8K | $33.75K |
| Sep 29, 2026 | Paulson John A.Director | Stock Award(Grant) at price 5.83 per share. | 10.7K | $62.50K |
| Sep 29, 2026 | Wechsler Amy BDirector | Stock Award(Grant) at price 5.83 per share. | 1.2K | $6.87K |
| Aug 18, 2026 | Lenar Aimee JOfficer | Sale at price 7.03 per share. | 36.8K | $258.89K |
| Jun 29, 2026 | Leung SandraDirector | Stock Award(Grant) at price 4.93 per share. | 6.8K | $33.75K |
| Jun 29, 2026 | Paulson John A.Director | Stock Award(Grant) at price 4.93 per share. | 12.7K | $62.50K |
| May 21, 2026 | Roberts Eiry WynDirector | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 21, 2026 | Goettler MichaelDirector | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 21, 2026 | Lee Frank DonDirector | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 21, 2026 | Garcia Christian ADirector | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 21, 2026 | Leung SandraDirector | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 21, 2026 | Power Robert NDirector | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 21, 2026 | Paulson John A.Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 21, 2026 | Wechsler Amy BDirector | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 21, 2026 | Kavanagh Sarah BaldwinDirector | Stock Award(Grant) at price 0.00 per share. | 45.9K | — |
| May 18, 2026 | Lee Frank DonDirector | Sale at price 5.43 per share. | 24.5K | $132.80K |
| Mar 30, 2026 | Leung SandraDirector | Stock Award(Grant) at price 5.40 per share. | 5.9K | $32.11K |
| Mar 30, 2026 | Paulson John A.Director | Stock Award(Grant) at price 5.40 per share. | 11.6K | $62.50K |
| Mar 30, 2026 | Wechsler Amy BDirector | Stock Award(Grant) at price 5.40 per share. | 1.3K | $6.87K |
| Mar 2, 2026 | Carson Seana LynneGeneral Counsel | Sale at price 5.77 - 5.78 per share. | 11.3K | $65.13K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.4 | 3.3 | -8.9 | 5.9 | -6.3 | -8.0 | 39.8 | -7.5 | -8.5 | 0.7 | −15.5% | ||
| 2025 | -7.8 | 0.1 | -13.0 | -18.1 | -14.5 | 47.0 | -11.6 | 26.0 | -13.1 | 8.8 | -9.5 | 9.4 | −13.8% |
| 2024 | -2.1 | 19.6 | 13.0 | -17.4 | -25.1 | 6.2 | -13.5 | -1.7 | 37.6 | 12.7 | -9.0 | -3.7 | +0.5% |
| 2023 | 22.6 | 20.9 | -13.0 | -9.0 | 11.4 | -2.6 | 21.4 | -14.1 | -1.4 | -17.0 | 4.7 | 12.3 | +27.7% |
| 2022 | -11.0 | -2.1 | -5.0 | -16.8 | -48.9 | -14.0 | -44.7 | 29.2 | 15.4 | -5.7 | 8.2 | -10.7 | −77.3% |
| 2021 | 22.6 | 23.2 | 1.0 | 1.4 | -0.0 | -8.8 | -0.2 | -0.4 | -4.4 | 0.8 | -15.1 | 15.8 | +32.7% |
| 2020 | -8.3 | -19.3 | -30.0 | 16.9 | 2.0 | -1.0 | -0.1 | -9.0 | -6.5 | 6.2 | 12.5 | 12.0 | −30.5% |
| 2019 | 32.9 | -3.5 | 4.2 | -6.5 | -10.2 | 21.7 | -5.0 | -11.0 | 2.4 | 13.7 | 13.7 | 5.9 | +62.0% |
| 2018 | -10.9 | -11.5 | -2.9 | 13.5 | 21.7 | 5.6 | -6.5 | 6.3 | 11.1 | -10.9 | 6.4 | -24.1 | −11.1% |
| 2017 | -5.1 | 4.4 | -23.3 | -16.1 | 30.3 | 43.6 | -4.9 | -18.5 | 6.8 | -18.4 | 43.3 | 24.1 | +43.1% |
| 2016 | -11.2 | -27.1 | -60.0 | 26.8 | -14.7 | -29.2 | 10.7 | 30.2 | -15.4 | -27.3 | -11.5 | -8.0 | −85.7% |
| 2015 | 11.8 | 23.4 | 0.6 | 9.2 | 10.1 | -7.0 | 15.9 | -10.5 | -22.6 | -47.4 | -4.1 | 13.0 | −29.0% |
| 2014 | 15.5 | 6.8 | -9.0 | 1.4 | -1.9 | -3.9 | -6.9 | -0.1 | 11.8 | 1.4 | 9.3 | -1.6 | +21.9% |
| 2013 | 11.0 | 1.7 | 11.2 | 1.4 | 19.8 | -5.5 | 8.7 | 5.1 | 6.1 | 1.3 | 3.7 | 7.1 | +96.4% |
| 2012 | 3.9 | 9.1 | 1.5 | 3.6 | -12.5 | -8.0 | 6.2 | 7.8 | 7.8 | 1.2 | -1.2 | 8.1 | +28.0% |
| 2011 | 29.1 | 9.7 | 24.3 | 5.7 | -0.5 | -0.8 | 5.9 | -18.3 | -17.5 | 6.6 | 16.8 | 1.0 | +65.0% |
| 2010 | 4.0 | 2.1 | 13.1 | 1.4 | -11.7 | 28.2 | 13.8 | 4.5 | 9.5 | 10.2 | -6.3 | 9.4 | +102.7% |
| 2009 | 15.7 | -3.5 | 3.8 | 0.4 | 15.7 | 5.7 | -0.4 | -5.0 | 21.3 | -12.8 | 7.2 | -3.3 | +47.7% |
| 2008 | 1.8 | 3.4 | -24.8 | 7.4 | 2.5 | -17.7 | 5.2 | 5.4 | -8.7 | -12.0 | -0.6 | 10.5 | −29.8% |
| 2007 | -3.7 | 1.8 | 5.3 | 11.6 | -0.5 | 4.8 | -24.9 | -8.2 | -0.9 | 15.2 | -23.6 | -12.0 | −36.4% |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Buy / hold / sell counts